Abstract
Introduction
With a considerable patient population and continued government focus on
lowering national smoking rates, the nicotine dependence market represents a
lucrative opportunity for pharmaceutical companies. With strong uptake since
launch in 2006 of Pfizer' s Chantix (varenicline), the seven major prescription
nicotine dependence market was estimated to total $1.35 billion in 2008.
Key reasons to purchase this research
- Benchmark key late-stage pipeline nicotine dependence projects against
current market leading brands, supported by insight from key opinion leaders.
- Quantify the future market landscape with sales forecasts of marketed,
generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.
- Understand key events impacting the future nicotine dependence
prescription drug market
| 
View Cart
